专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011024620A1 ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：抗生物药物组合物
公开(公告)号：WO2011024620A1
公开(公告)日：2011-03-03
申请号：PCT/JP2010/063230
申请日：2010-07-29
申请人： POLA PHARMA INC. , NIHON NOHYAKU CO., LTD. , KOBAYASHI, Hirokazu , KUBOTA, Nobuo
发明人： KOBAYASHI, Hirokazu , KUBOTA, Nobuo
IPC分类号： A61K31/4178 , A61P17/00 , A61P31/10 , A61K47/08
CPC分类号： A61K31/4178 , A61K9/0014 , A61K47/08 , A61P17/00 , A61P31/10
摘要： A pharmaceutical composition which comprises 1) a compound represented by the following general formula (1) and/or a salt thereof; and 2) a ketone such as methyl ethyl ketone. Preferably, the compound represented by the following general formula (1) is luliconazole, where R 1 =R 2 =a chlorine atom: where R 1 and R 2 each independently represents a hydrogen atom or a halogen atom, and at least one of R 1 and R 2 represents a halogen atom. The present invention provides a preparation excellent in solubilization stability for a compound represented by the general formula (1) and/or a salt thereof in low-temperature or high-temperature storage.
摘要翻译：一种药物组合物，其包含1）由以下通式（1）表示的化合物和/或其盐; 和2）酮如甲基乙基酮。优选地，由以下通式（1）表示的化合物是卢立康唑，其中R 1 = R 2 =氯原子：其中R 1和R 2各自独立地表示氢原子或卤素原子，并且R 1和R 2中的至少一个表示卤素原子。本发明提供了在低温或高温储存中对通式（1）表示的化合物和/或其盐的增溶稳定性优异的制剂。

2. 发明申请

WO2010117091A2 ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：抗生物药物组合物
公开(公告)号：WO2010117091A2
公开(公告)日：2010-10-14
申请号：PCT/JP2010/056884
申请日：2010-04-09
申请人： POLA PHARMA INC. , NIHON NOHYAKU CO., LTD. , KOBAYASHI, Hirokazu , KOSUGI, Eiko , KUBOTA, Nobuo
发明人： KOBAYASHI, Hirokazu , KOSUGI, Eiko , KUBOTA, Nobuo
IPC分类号： A61K9/08
CPC分类号： A61K9/7015 , A61K9/0014 , A61K9/08 , A61K31/4178
摘要： In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25°C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrroridone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a steroisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60 degrees C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20°C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5°C. for 2 weeks after manufacture.
摘要翻译：在含有诸如卢立康唑和/或其盐的化合物的外用药物组合物中，包含在1atm和25℃处于液体状态的高级醇。和/或二元酸的二酯，条件是不含碳酸二酯，聚氧乙烯烷基醚和/或聚氧乙烯烯基醚。本发明提供使用克罗他米通以外的溶剂，碳酸丙烯酯和N-甲基-2-吡咯烷酮作为增溶和空间稳定化的溶剂的制剂，具有以下性质：1）当由通式（1）表示的化合物和 /或其盐具有立体异构体，在60℃的保存条件下生产的化合物和/或其盐的立体异构体的量为3周时相对于总质量为1质量％化合物和/或其盐在保存开始时; 2）当在20℃的恒定温度下保存时，制剂处于澄清的液体状态。制造后立即生产; 和3）当制剂在5℃保存时，不沉积晶体。制造后2周。

3. 发明申请

WO2010117089A2 ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：抗生物药物组合物
公开(公告)号：WO2010117089A2
公开(公告)日：2010-10-14
申请号：PCT/JP2010/056881
申请日：2010-04-09
申请人： POLA PHARMA INC. , NIHON NOHYAKU CO., LTD. , KOBAYASHI, Hirokazu , KOSUGI, Eiko , KUBOTA, Nobuo
发明人： KOBAYASHI, Hirokazu , KOSUGI, Eiko , KUBOTA, Nobuo
IPC分类号： A61K9/08
CPC分类号： A61K31/4178 , A61K9/0014 , A61K9/08 , A61K9/7015 , A61K47/08 , A61K47/10 , A61K47/14
摘要： In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60°C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20°C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5°C. for 2 weeks after manufacture.
摘要翻译：在含有5质量％以上的化合物如卢立康唑和/或其盐的外用药物组合物中，丙酮，聚氧乙烯烷基（碳原子数为8〜30）的醚，以及 /或聚氧乙烯烯基（碳原子数为8〜30）的醚。本发明提供使用克罗他米通以外的溶剂，碳酸丙烯酯和N-甲基-2-吡咯烷酮作为增溶和空间稳定化溶剂的制剂，具有以下性质：1）当由通式（1）表示的化合物和 /或其盐具有立体异构体，在60℃的保存条件下产生的化合物和/或其盐的立体异构体的量。相对于保存开始时的化合物和/或其盐的总质量，3周为1质量％以下。 2）当在20℃的恒定温度下保存时，制剂处于澄清的液体状态。制造后立即生产; 和3）当制剂在5℃保存时，不沉积晶体。制造后2周。

4. 发明申请

WO2011155640A1 ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：抗生物药物组合物
公开(公告)号：WO2011155640A1
公开(公告)日：2011-12-15
申请号：PCT/JP2011/063860
申请日：2011-06-10
申请人： POLA PHARMA INC. , NIHON NOHYAKU CO., LTD. , KUBOTA, Nobuo , KOBAYASHI, Hirokazu , MASUDA, Takaaki
发明人： KUBOTA, Nobuo , KOBAYASHI, Hirokazu , MASUDA, Takaaki
IPC分类号： A61K9/06 , A61K9/08 , A61K9/10 , A61K9/12 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/48 , A61K31/385 , A61K31/4178 , A61K47/10 , A61K47/14 , A61K47/34 , A61K47/44
CPC分类号： A61K31/4178 , A61K9/0014 , A61K9/08 , A61K31/385 , A61K47/10 , A61K47/14 , A61K47/22
摘要： An object is to provide a medicament preparation which is excellent in the solubilization stability in relation to a compound represented by the general formula (1) during the storage in a low temperature region and a high temperature region. The present invention resides in a pharmaceutical composition comprising 1) the compound represented by the general formula (1) and/or a salt thereof and 2) a polyhydric alcohol derivative. General formula (1) (In the formula, R 1 , R 2 independently represent hydrogen atom or halogen atom respectively, and at least one of R 1 , R 2 is halogen atom.)
摘要翻译：本发明提供一种药物制剂，其在低温区域和高温区域的储存过程中，相对于由通式（1）表示的化合物的溶解稳定性优异。本发明涉及一种药物组合物，其包含1）由通式（1）表示的化合物和/或其盐和2）多元醇衍生物。通式（1）（式中，R 1，R 2分别独立地表示氢原子或卤原子，R 1，R 2中的至少一个为卤素原子）

5. 发明申请

WO2014185542A1 PHARMACEUTICAL COMPOSITION FOR TREATING VAGINITIS OR PNEUMONIA 审中-公开
标题翻译：用于治疗VAGINITIS或PNEUMONIA的药物组合物
公开(公告)号：WO2014185542A1
公开(公告)日：2014-11-20
申请号：PCT/JP2014/063138
申请日：2014-05-13
申请人： POLA PHARMA INC. , NIHON NOHYAKU CO., LTD.
发明人： KOBAYASHI, Hirokazu
IPC分类号： A61K31/4178 , A61K9/20 , A61K9/28 , A61P31/10 , A61K31/165 , A61P31/04 , A61P11/02 , A61P15/02 , A61K9/02 , A61K9/48
CPC分类号： A61K31/4178 , A61K9/0007 , A61K9/02 , A61K31/165 , A61K2300/00
摘要： Provided is a pharmaceutical composition in which an action of a compound represented by a general formula (1) is enhanced, and which is effective for pneumonia and vaginitis. Disclosed is a pharmaceutical composition for vaginitis or pneumonia, comprising a compound represented by the following general formula (1) and crotamiton: (in the formula, each of R1 and R2 independently represents hydrogen atom or halogen atom, and R1 and R2 are not simultaneously hydrogen atoms.)
摘要翻译：本发明提供一种药物组合物，其中由通式（1）表示的化合物的作用增强，对肺炎和阴道炎有效。公开了一种用于阴道炎或肺炎的药物组合物，其包含由以下通式（1）表示的化合物和克罗他米通：（在该式中，R 1和R 2各自独立地表示氢原子或卤素原子，并且R 1和R 2不同时氢原子）

6. 发明申请

WO2014042043A1 PHARMACEUTICAL COMPOSITION CONTAINING LULICONAZOLE 审中-公开
标题翻译：含有LULICONAZOLE的药物组合物
公开(公告)号：WO2014042043A1
公开(公告)日：2014-03-20
申请号：PCT/JP2013/073731
申请日：2013-08-28
申请人： POLA PHARMA INC. , NIHON NOHYAKU CO., LTD.
发明人： MASUDA, Takaaki , KOBAYASHI, Hirokazu
IPC分类号： A61K31/4178
CPC分类号： A61K47/14 , A61K9/0014 , A61K9/06 , A61K31/4178 , A61K45/06 , A61K47/08 , A61K47/10 , A61K47/12 , A61K47/22 , A61K47/34 , A61K2300/00
摘要： Means for controlling the formation amount of a formed amide form in relation to a pharmaceutical composition containing luliconazole is provided. Disclosed is a pharmaceutical composition containing 1) luliconazole and 2) one component or two or more components selected from carboxylic acid and derivative thereof, ketone, phosphoric acid and derivative thereof, local anesthetic, antihistamine, and POE-based nonionic surfactant; wherein a content of an amide derivative of luliconazole is not more than 0.2% by mass with respect to a charged amount of luliconazole after storage at 60°C for 3 weeks or at 40°C for 6 months.
摘要翻译：提供了用于控制形成酰胺形式相对于含有卢立康唑的药物组合物形成量的方法。公开了含有1）柳替康唑和2）选自羧酸及其衍生物，酮，磷酸及其衍生物，局部麻醉剂，抗组胺剂和POE类非离子表面活性剂的一种或两种以上成分的药物组合物。其中相对于在60℃下保存3周或在40℃下6个月后，伏立康唑的加入量，卢立康唑的酰胺衍生物的含量不超过0.2质量％。

7. 发明申请

WO2008084650A2 PHOTOSENSOR 审中-公开
标题翻译：光传感器
公开(公告)号：WO2008084650A2
公开(公告)日：2008-07-17
申请号：PCT/JP2007/074587
申请日：2007-12-14
申请人： CASIO COMPUTER CO., LTD. , MATSUMOTO, Hiroshi , YAMAGUCHI, Ikuhiro , KOBAYASHI, Hirokazu
发明人： MATSUMOTO, Hiroshi , YAMAGUCHI, Ikuhiro , KOBAYASHI, Hirokazu
IPC分类号： H01L31/0224 , H01L31/0392 , H01L31/113
CPC分类号： H01L31/022408 , H01L27/14678 , H01L31/03921 , H01L31/1136 , Y02E10/50
摘要： A photosensor includes a semiconductor thin film (5) for photoelectric conversion having a first side portion and a second side portion. A source electrode (9) extends in the longitudinal direction of the semiconductor thin film (5) and has a side edge portion (9b, 9c) that overlaps the first side portion of the semiconductor thin film (5), and a drain electrode (10) extends in the longitudinal direction and has a side edge portion (10b, 10c) that overlaps the second side portion of the semiconductor thin film (5). At least one of the side edge portions (9b, 9c, 10b, 10c) of the source and drain electrodes (9, 10) has protruding portions (9b, 10b) which are arranged along the longitudinal direction and which overlap the semiconductor thin film (5), and notched portions (9c, 10c) formed between the protruding portions (9b, 10b). An ohmic contact layer (7, 8) is formed between the semiconductor thin film (5) and the protruding portions (9b, 10b) of the at least one of the side edge portions (9b, 9c, 10b, 10c) of the source and drain electrodes (9, 10).
摘要翻译：光电传感器包括用于光电转换的半导体薄膜（5），其具有第一侧部分和第二侧部分。源电极（9）沿半导体薄膜（5）的纵向延伸并且具有与半导体薄膜（5）的第一侧部重叠的侧边部（9b，9c）和漏电极（ 10）沿纵向延伸并具有与半导体薄膜（5）的第二侧部重叠的侧边部（10b，10c）。源电极和漏电极（9,10）的侧边缘部分（9b，9c，10b，10c）中的至少一个具有沿着纵向方向布置的突出部分（9b，10b），其与半导体薄膜（5）以及形成在突起部分（9b，10b）之间的凹口部分（9c，10c）。在半导体薄膜（5）与源极的至少一个侧边缘部分（9b，9c，10b，10c）的突出部分（9b，10b）之间形成欧姆接触层（7,8）和漏电极（9,10）。

8. 发明申请

WO2003088615A2 MOBILE NODE AND METHOD FOR MOBILE COMMUNICATIONS 审中-公开
标题翻译：移动通信的移动节点和方法
公开(公告)号：WO2003088615A2
公开(公告)日：2003-10-23
申请号：PCT/JP2003/004898
申请日：2003-04-17
申请人： MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. , FUNABIKI, Makoto , IKEDA, Shinkichi , MATSUMOTO, Taisuke , KIMURA, Yasunari , KOBAYASHI, Hirokazu
发明人： FUNABIKI, Makoto , IKEDA, Shinkichi , MATSUMOTO, Taisuke , KIMURA, Yasunari , KOBAYASHI, Hirokazu
IPC分类号： H04L29/06
CPC分类号： H04W60/00 , H04L45/04 , H04L45/121 , H04L45/20 , H04L69/16 , H04L69/161 , H04L69/167 , H04W8/065 , H04W60/06 , H04W80/04
摘要： In a mobile communication system supported with IP version 6, a mobile node (10) measures at least one of a hop number or communication delay time to a belonging home agent (11). When the result of measurement is equal to or greater than a predetermined value, registration deletion is requested to the belonging home agent (11) while registration is requested to a new home agent (14). The belonging home agent (11) deletes the registration of mobile node (10), and the new home agent (14) registers the mobile node. This can reduce the load on an IP network (18) and decrease data delay.
摘要翻译：在由IP版本6支持的移动通信系统中，移动节点（10）测量归属代理（11）的跳数或通信延迟时间中的至少一个。当测量结果等于或大于预定值时，向归属代理（11）请求注册删除，同时向新的归属代理（14）请求注册。归属代理（11）删除移动节点（10）的注册，新的归属代理（14）登记移动节点。这可以减少IP网络上的负载（18）并减少数据延迟。

9. 发明申请

WO2012101980A1 SOLID-LIQUID SEPARATION DEVICE 审中-公开
标题翻译：固液分离装置
公开(公告)号：WO2012101980A1
公开(公告)日：2012-08-02
申请号：PCT/JP2012/000237
申请日：2012-01-17
申请人： AMUKON KABUSHIKI KAISHA , KANEKO, Kazuo , TEZUKA, Yusuke , NAKAMURA, Yoshitaka , KADOWAKI, Yuki , KOBAYASHI, Hirokazu
发明人： KANEKO, Kazuo , TEZUKA, Yusuke , NAKAMURA, Yoshitaka , KADOWAKI, Yuki , KOBAYASHI, Hirokazu
IPC分类号： B30B9/26 , B30B9/12
CPC分类号： B30B9/121 , B01D25/127 , B01D29/35 , B01D29/46 , B01D29/52 , B01D29/6476 , B01D29/828 , B30B9/12 , B30B9/14 , B30B9/26
摘要： A solid-liquid separation device includes a plurality of fixed members and movable members that are movably disposed between the adjacent fixed members, and moreover a screw extending through the fixed members and the movable members in a state where the screw is not in contact with the fixed members and the movable members. The screw is rotationally driven about a center axis line thereof. Following the rotation of the screw, an object to be treated that has penetrated into a solid-liquid separation portion demarcated by the fixed members and the movable members is caused to move toward an outlet of the solid-liquid separation portion, a filtrate separated from the object is discharged to the outside of the solid-liquid separation portion through filtrate discharge gaps between the fixed members and the movable members, and the object that has a reduced liquid content ratio is discharged from the outlet to the outside of the solid-liquid separation portion. In order to increase significantly a dewatering ratio of the object, the movable members are formed to move while penetrating closer to the center axis line of the screw than an outer circumferential edge of the blade of the screw, without coming into contact with the screw.
摘要翻译：固液分离装置包括可移动地设置在相邻的固定构件之间的多个固定构件和可动构件，以及在螺钉不与其接触的状态下延伸穿过固定构件和可动构件的螺钉固定构件和可移动构件。螺杆围绕其中心轴线被旋转地驱动。在螺杆旋转之后，使已经渗透到由固定部件和可移动部件划分的固液分离部分中的待处理物体朝向固液分离部分的出口移动，滤液与物体通过固定部件和可动部件之间的滤液排出间隙排出到固液分离部分的外部，并且具有降低的液体比例的物体从出口到固体液体的外部排出分离部分。为了显着提高物体的脱水率，可移动构件形成为在与螺钉的螺钉接触的同时比螺杆的叶片的外周边缘更靠近螺钉的中心轴线的方向移动。

10. 发明申请

WO2003088615A3 MOBILE NODE, ROUTER, SERVER AND METHOD FOR MOBILE COMMUNICATIONS UNDER IP VERSION 6 (IPV6) PROTOCOL 审中-公开
公开(公告)号：WO2003088615A3
公开(公告)日：2003-10-23
申请号：PCT/JP2003/004898
申请日：2003-04-17
申请人： MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. , FUNABIKI, Makoto , IKEDA, Shinkichi , MATSUMOTO, Taisuke , KIMURA, Yasunari , KOBAYASHI, Hirokazu
发明人： FUNABIKI, Makoto , IKEDA, Shinkichi , MATSUMOTO, Taisuke , KIMURA, Yasunari , KOBAYASHI, Hirokazu
IPC分类号： H04L29/06
摘要： In a mobile communication system supported with IP version 6, a mobile node (10) measures at least one of a hop number or communication delay time to a belonging home agent (11). When the result of measurement is equal to or greater than a predetermined value, registration deletion is requested to the belonging home agent (11) while registration is requested to a new home agent (14). The belonging home agent (11) deletes the registration of mobile node (10), and the new home agent (14) registers the mobile node. This can reduce the load on an IP network (18) and decrease data delay.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式